All In Biotech

Drug Trial Radar · NCT05848687

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Nov 3, 2023

Primary completion

Dec 2028

Study completion Dec 2033

Sponsor

Lead sponsor
Tanja Andrea GruberAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Pediatric Oncology Experimental Therapeutics Investigators' Consortium; Amgen; Lucile Packard Foundation for Children's Health; Kura Oncology, Inc.; United States Department of Defense; Cannonball Kid's Cancer
First posted
May 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 1 year
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia cells outer membrane.

Conditions

  • Lymphoblastic Leukemia

Interventions

  • DexamethasoneDrug

    Given orally (PO) or naso-gastrically (NG) or intravenously (IV).

  • MitoxantroneDrug

    Given IV

  • PEG asparaginaseDrug

    Given IV

  • BortezomibDrug

    Given IV

  • VorinostatDrug

    Taken PO or NG

  • MercaptopurineDrug

    Given PO or NG.

  • MethotrexateDrug

    Given IV, IM or PO

  • BlinatumomabDrug

    Will be administered at 15 mcg/m2/day for 28 days following induction and reinduction

  • ZiftomenibDrug

    3+3 dose escalation will be done. Dose level 1 will start at 75% of the adult recommended phase two dosing which has been established in phase I studies. Based on tolerability, we will either de-escalate to 50% RP2D (dose level -1) or escalate to 100% RP2D

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Minimal Residual DiseaseTime frame: 5 years and 2 months

Locations

24 sites in 2 countries. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital

    Phoenix, Arizona · Recruiting

  • Arkansas Children's Hospital

    Little Rock, Arkansas · Recruiting

  • Children's Hospital Los Angeles

    Los Angeles, California · Recruiting

  • Valley Children's Hospital

    Madera, California · Recruiting

  • Children's Hospital of Orange County

    Orange, California · Recruiting

  • Stanford University

    Palo Alto, California · Recruiting

  • Rady Children's Hospital San Diego

    San Diego, California · Recruiting

  • Arnold Palmer Hospital for Children

    Orlando, Florida · Recruiting

  • Children's Hospital of Minnesota

    Minneapolis, Minnesota · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Novant Health - Hemby Children's Hospital

    Charlotte, North Carolina · Not yet recruiting

  • Doernbecher Children's Hospital

    Portland, Oregon · Recruiting

  • Penn State Milton S Hershey Medical Center

    Hershey, Pennsylvania · Recruiting

  • MD Anderson

    Houston, Texas · Recruiting

  • University of Texas Health Science Center San Antonio

    San Antonio, Texas · Recruiting

  • University of Utah Huntsman Cancer Institute

    Salt Lake City, Utah · Recruiting

  • Children's Hospital of The King's Daughters

    Norfolk, Virginia · Recruiting

  • Alberta Children's Hospital

    Calgary, Alberta, Canada · Not yet recruiting

  • Stollery Children's Hospital

    Edmonton, Alberta, Canada · Not yet recruiting

  • BC Children's Hospital

    Vancouver, British Columbia, Canada · Not yet recruiting

  • McMaster Children's Hospital

    Hamilton, Ontario, Canada · Not yet recruiting

  • CHU Sainte-Justine

    Montreal, Quebec, Canada · Not yet recruiting

  • Montreal Children's Hospital

    Montreal, Quebec, Canada · Not yet recruiting

  • Chu De Quebec

    Québec, Quebec, Canada · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.